C83.59
Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Lymphoblastic (diffuse) lymphoma, classified under ICD-10 code C83.59, is a type of non-Hodgkin lymphoma that originates from lymphoid tissues. Unlike lymphomas that develop within lymph nodes, this form can occur outside lymphatic structures, affecting various organs and tissues away from the lymphatic system. It is characterized by rapid growth and a highly aggressive course, often requiring prompt diagnosis and treatment.
Causes & Symptoms
Clinical Causes: Genetic mutations in lymphoid cells Exposure to certain chemicals or radiation Immunodeficiency conditions Previous history of lymphoma or other cancers Age-related immune changes
Key Symptoms: Swelling or a lump in the affected area Unexplained weight loss Fever that persists over time Night sweats Fatigue and weakness Pain or discomfort in the affected organ or tissue Difficulty breathing if the chest is involved Abdominal discomfort or swelling if the abdomen is affected Symptoms related to specific organ involvement, such as skin lesions or neurological symptoms
Diagnostic & Treatment
Diagnosis Path: The diagnosis process typically involves several approaches to confirm the presence of lymphoma and identify its extent: - Physical Examination: Assessing for swollen lymph nodes or abnormal lumps - Imaging Tests: CT scans, PET scans, or MRI to visualize affected areas - Biopsy: Extracting tissue samples for microscopic examination to identify malignant lymphocytes - Laboratory Tests: Blood tests to evaluate overall health and detect markers associated with lymphoma - Bone Marrow Biopsy: To check if the cancer has spread to the marrow - Additional tests may include molecular and genetic studies to understand specific cancer characteristics
Treatment Protocols: Management of lymphoblastic (diffuse) lymphoma at extranodal and solid organ sites typically involves systemic therapies: - Chemotherapy: The mainstay treatment to destroy lymphoma cells - Targeted Therapy: Drugs designed to target specific molecules involved in cancer growth - Immunotherapy: Boosting the body's immune response to fight the cancer - Radiation Therapy: Used selectively, primarily when localized to a specific site - Stem Cell Transplant: In some cases, high-dose chemotherapy followed by stem cell replacement may be considered - Supportive Care: Managing side effects and maintaining quality of life Treatment plans are personalized, taking into account the patient’s overall health, extent of disease, and specific organ involvement.
Clinical Advice & FAQs
Billing Guidance
Is C83.59 a billable ICD-10 code?
Yes, C83.59 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.59?
Clinical documentation must specify the nature of Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference